P a vaccine system J Natl Cancer Inst. 1976; 56:69700. [PubMed: 176406] 2. Cohen JI

May 3, 2024

P a vaccine program J Natl Cancer Inst. 1976; 56:69700. [PubMed: 176406] 2. Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an essential vaccine target for cancer prevention. Sci Transl Med. 2011; 3:107fs7. three. Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM, Motz M, Wolf H. First EBV vaccine trial in humans applying recombinant vaccinia virus expressing the important membrane antigen. Dev Biol Stand. 1995; 84:17177. [PubMed: 7796951] 4. Maurer DM, Harrington B, Lane JM. Smallpox vaccine: contraindications, administration, and adverse reactions. Am Fam Physician. 2003; 68:88996. [PubMed: 13678138] 5. Jackman WT, Mann KA, Hoffmann HJ, Spaete RR. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine. 1999; 17:66068. [PubMed: 10067671] six. Moutschen M, Leonard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthful adults. Vaccine. 2007; 25:4697705. [PubMed: 17485150] 7 . Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M.Cephalomannine In stock Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the security, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthful young adults. J Infect Dis. 2007; 196:1749753. The initial phase 2 trial of gp350 EBV vaccine that demonstrated safety, immunogenicity and protection against infectious mononucleosis.BMS-986278 supplier [PubMed: 18190254] 8.PMID:24190482 Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, et al. A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation. 2009; 88:1025029. [PubMed: 19855249] 9. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localization of Epstein-Barr virus cytotoxic T cell epitopes applying recombinant vaccinia: implications for vaccine improvement. J Exp Med. 1992; 176:16976. [PubMed: 1377222] 10. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus- certain cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA three). J Exp Med. 1990; 171:34549. [PubMed: 1688611] 11 Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008; 82:1448457. A feasibility trial that demonstrated safety and immunogenicity of an EBV CD8+ T-cell peptide vaccine. Even though not practical for basic use as a result of HLA restriction, it could possibly be studied in subjects whose HLA is nicely characterized, which include pretransplant candidates. [PubMed: 18032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma sufferers. Cancer Res. 2013; 73:1676688. A completely made trial whose hypothesis is the fact that enhanced recognition of tumor cells by way of their expression of EBNA antigens EBNA-1 and LMP-2 will probably be therapeutic. Safety, immunogenicity, and a dose-response effect were demonstrated. [PubMed: 23348421] 13. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious m.